First FCNCN Q1 2026 Beat Revenue NA EPS Exceeds by Significant Fortress Biotech FBIO Q4 2025 Results Fall Short EPS 001 Revenue NA Oil Rallies as USIran Negotiations Remain Deadlocked CMS Energy CMSD Crushes Q1 2026 Estimates EPS 113 Tops Views ADP Private Payrolls Rise 109000 in April Exceeding Market Forecasts Wes Streeting Proposes Capital Gains Tax Reform in Labour Leadership Bid Vodafone Idea Among 6 Midcap Stocks Hitting 52Week Highs with Up to 50 Rally South Koreas Deputy PM Warns AI Wealth Must Benefit Public Amid Samsung Labor Unrest Earnings Season Heats Up Key Reports and Analyst Estimates to Watch AIRelated Layoffs May Not Boost Stocks as Expected Data Suggests TMCI Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Surprise Despite Stock Decline RPM Q1 2026 Earnings Stellar EPS Surprise of 5993 Drives Stock Higher Oscar Health Inc OSCR Q1 2026 Earnings Massive EPS Beat Signals Strong Underwriting FHN Q1 2026 Earnings EPS Beats Estimates by Over 6 TKNO Q1 2026 Earnings EPS Beat Amid Cost Discipline PFXNZ Q1 2026 Earnings Strong EPS Beat Driven by Solid Investment Income Doximity Inc DOCS Holds Near Support After Modest Decline Cal Redwood Acquisition Corp CRAQ Holds Steady at 1026 Amid Minimal Price Movement Phathom Pharmaceuticals PHAT Faces Selling Pressure Nears Key Support After 216 Decline Chime Financial CHYM Edges Lower as Key Support Level Comes into Focus Terra Income Fund Notes TFSA Surge 554 as FixedIncome Market Rebounds ASPN Q1 2026 Earnings EPS Misses Consensus Stock Climbs 585 on Strategic Momentum Agilysys Q1 2026 Earnings EPS Surpasses Expectations by 244 Amid Concerns Over Revenue Disclosure Kyntra Bio Inc KYNB Q1 2026 Earnings PreRevenue Biotech Misses EPS Estimates as Stock Edges Higher Camden National Corporation CAC Q1 2026 Earnings EPS Beats Estimates Amid Slightly Negative Market Reaction CSV Q1 2026 Earnings Slight EPS Beat Amid Mixed Market Reaction Diamondback Energy Capitalizes on Oil Price Surge Amid Supply Disruptions Armata Pharmaceuticals ARMP Q1 2026 Earnings Massive EPS Miss as PreRevenue Biotech Struggles with Costs Oxbridge Re Holdings Warrant OXBRW Holds at 011 Amid Low Volatility